Simvastatin generic drugs expanding their presence in domestic anti-hyperlipemia drug market
Published: 2003-12-17 07:00:00
Updated: 2003-12-17 07:00:00
Following the patent expiration of MSD Korea's Zocor, a number of domestic pharmaceutical firms have been rushing to release simvastatin generic versions this year and as a result, their market share is rapidly increasing by more than 70 percent with the combined sales of 16.0 billion won.
The...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
